Literature DB >> 15520004

Distinct molecular mechanisms for agonist peptide binding to types A and B cholecystokinin receptors demonstrated using fluorescence spectroscopy.

Kaleeckal G Harikumar1, Jeremy Clain, Delia I Pinon, Maoqing Dong, Laurence J Miller.   

Abstract

Fluorescence spectroscopy provides a direct method for evaluating the environment of a fluorescent ligand bound to its receptor. We utilized this methodology to determine the environment of Alexa within a cholecystokinin (CCK)-like probe (Alexa488-Gly-[(Nle(28,31))CCK-26-33]; CCK-8 probe) bound to the type A CCK receptor (Harikumar, K. G., Pinon, D. L., Wessels, W. S., Prendergast, F. G., and Miller, L. J. (2002) J. Biol. Chem. 277, 18552-18560). Here, we study this probe at the type B CCK receptor and develop another probe with its fluorophore closer to the carboxyl-terminal pharmacophore of type B receptor ligands (Alexa488-Trp-Nle-Asp-Phe-NH2; CCK-4 probe). Both probes bound to type B CCK receptors in a saturable and specific manner and represented full agonists. Similar to the type A receptor, at the type B receptor these probes exhibited shorter lifetimes and lower anisotropy when the receptor was in the active conformation than when it was shifted to its inactive, G protein-uncoupled state using guanosine 5'-[beta,gamma-imido]-triphosphate trisodium salt. Absolute values for lifetime and anisotropy were lower for the CCK-8 probe bound to the type B receptor than for this probe bound to the type A receptor, and Alexa fluorescence was more easily quenched by iodide at the type B receptor. This represents the first direct evidence that, despite having identical affinities for binding and potencies for activating type A and B receptors, CCK is docked via distinct mechanisms, with the amino terminus more exposed to the aqueous milieu when bound to the type B CCK receptor than to the type A CCK receptor. Of interest, despite this difference in binding, activation of both receptors results in analogous direction of movement of the fluorescent indicator probes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15520004     DOI: 10.1074/jbc.M409480200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  Differential sensitivity of types 1 and 2 cholecystokinin receptors to membrane cholesterol.

Authors:  Ross M Potter; Kaleeckal G Harikumar; S Vincent Wu; Laurence J Miller
Journal:  J Lipid Res       Date:  2011-10-21       Impact factor: 5.922

2.  Transmembrane segment peptides can disrupt cholecystokinin receptor oligomerization without affecting receptor function.

Authors:  Kaleeckal G Harikumar; Maoqing Dong; Zhijie Cheng; Delia I Pinon; Terry P Lybrand; Laurence J Miller
Journal:  Biochemistry       Date:  2006-12-12       Impact factor: 3.162

3.  Development of a highly selective allosteric antagonist radioligand for the type 1 cholecystokinin receptor and elucidation of its molecular basis of binding.

Authors:  Maoqing Dong; Ashton M Vattelana; Polo C-H Lam; Andrew J Orry; Ruben Abagyan; Arthur Christopoulos; Patrick M Sexton; David R Haines; Laurence J Miller
Journal:  Mol Pharmacol       Date:  2014-10-15       Impact factor: 4.436

Review 4.  Fluorescent approaches for understanding interactions of ligands with G protein coupled receptors.

Authors:  Rajashri Sridharan; Jeffrey Zuber; Sara M Connelly; Elizabeth Mathew; Mark E Dumont
Journal:  Biochim Biophys Acta       Date:  2013-09-18

5.  Establishment of a mouse model for injury-induced scar formation and the accompanying chronic pain: Comprehensive microarray analysis of molecular expressions in fibrosis and hyperalgesia.

Authors:  Yuqiang Li; Hiroki Iida; Koji Kimata; Lisheng Zhuo; Akinobu Ota; Shinya Kimura; Xiaojian Yin; Masataka Deie; Takahiro Ushida
Journal:  Mol Pain       Date:  2019 Jan-Dec       Impact factor: 3.395

6.  Elimination of a cholecystokinin receptor agonist 'trigger' in an effort to develop positive allosteric modulators without intrinsic agonist activity.

Authors:  Aditya J Desai; Brad R Henke; Laurence J Miller
Journal:  Bioorg Med Chem Lett       Date:  2015-03-24       Impact factor: 2.823

7.  Direct demonstration of unique mode of natural peptide binding to the type 2 cholecystokinin receptor using photoaffinity labeling.

Authors:  Maoqing Dong; Laurence J Miller
Journal:  Peptides       Date:  2013-06-14       Impact factor: 3.750

8.  A type 1 cholecystokinin receptor mutant that mimics the dysfunction observed for wild type receptor in a high cholesterol environment.

Authors:  Aditya J Desai; Kaleeckal G Harikumar; Laurence J Miller
Journal:  J Biol Chem       Date:  2014-05-13       Impact factor: 5.157

9.  Membrane cholesterol affects stimulus-activity coupling in type 1, but not type 2, CCK receptors: use of cell lines with elevated cholesterol.

Authors:  Kaleeckal G Harikumar; Ross M Potter; Achyut Patil; Valerie Echeveste; Laurence J Miller
Journal:  Lipids       Date:  2013-01-11       Impact factor: 1.880

Review 10.  Structural basis of cholecystokinin receptor binding and regulation.

Authors:  Laurence J Miller; Fan Gao
Journal:  Pharmacol Ther       Date:  2008-05-11       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.